Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Lymphocyte Growth Factor [EPC]
Binetrakin is a recombinant human interleukin-12 (rhIL-12) acting as a potent lymphocyte growth factor. It is primarily utilized in clinical settings to modulate immune responses and stimulate hematopoietic recovery.
Name
Binetrakin
Raw Name
BINETRAKIN
Category
Lymphocyte Growth Factor [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Binetrakin
Binetrakin is a recombinant human interleukin-12 (rhIL-12) acting as a potent lymphocyte growth factor. It is primarily utilized in clinical settings to modulate immune responses and stimulate hematopoietic recovery.
Detailed information about Binetrakin
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Binetrakin.
In clinical practice, Binetrakin is classified as a biological response modifier. It is designed to mimic the effects of endogenous (naturally produced) IL-12. Its primary pharmacological role is to stimulate the proliferation and activation of T-lymphocytes and Natural Killer (NK) cells, which are essential for identifying and destroying pathogens and malignant cells. According to the FDA-approved pharmacological classifications, it is also associated with Interferon gamma [EPC] pathways, as IL-12 is the primary driver of interferon-gamma (IFN-γ) production in the body. The history of Binetrakin's development is rooted in oncology and hematology, where researchers sought to harness its potent immune-stimulating properties to treat various cancers and to assist in the recovery of the blood-forming system after severe insults, such as high-dose radiation or intensive chemotherapy.
At the molecular level, Binetrakin functions by binding to the interleukin-12 receptor (IL-12R), which is expressed on the surface of activated T-cells and NK cells. The IL-12 receptor is a complex composed of two subunits: IL-12Rβ1 and IL-12Rβ2. When Binetrakin binds to this receptor, it initiates a sophisticated intracellular signaling cascade known as the JAK-STAT pathway (Janus Kinase-Signal Transducer and Activator of Transcription). Specifically, it activates JAK2 and TYK2, which in turn phosphorylate STAT4.
Once phosphorylated, STAT4 molecules form dimers and translocate into the cell nucleus, where they act as transcription factors. This process leads to several critical biological outcomes:
The pharmacokinetic behavior of Binetrakin is characteristic of large protein biologics. Because it is a protein, it cannot be administered orally as the digestive system would break it down before it could be absorbed.
Binetrakin is primarily utilized in specialized clinical settings and clinical trials. Its FDA-recognized and investigational uses include:
Binetrakin is currently available only in injectable formats to ensure maximum stability and bioavailability:
> Important: Only your healthcare provider can determine if Binetrakin is right for your specific condition. The use of this medication requires strict clinical supervision and frequent laboratory monitoring.
The dosage of Binetrakin is highly individualized and depends strictly on the indication being treated, the patient's body weight, and their overall immune status.
Binetrakin is not currently approved for general use in pediatric populations. Its use in children is strictly limited to controlled clinical trials or emergency protocols under the 'Animal Rule' for radiation exposure. Pediatric dosing, when utilized, is typically calculated based on body surface area (BSA) or weight (mcg/kg) to ensure safety, as children may be more sensitive to cytokine-induced systemic inflammation.
Because Binetrakin is primarily cleared through proteolytic degradation rather than renal filtration, standard dose adjustments for mild to moderate renal impairment are often not required. However, in patients with end-stage renal disease (ESRD), clinicians monitor for signs of protein accumulation and systemic toxicity closely.
There are no specific dose adjustment guidelines for hepatic impairment; however, since IL-12 can induce the production of other cytokines that affect liver function, Binetrakin should be used with extreme caution in patients with pre-existing liver disease or elevated transaminases.
Clinical studies have not identified significant differences in the safety profile of Binetrakin between elderly and younger patients. However, because older adults are more likely to have decreased cardiac or pulmonary reserve, the systemic effects of cytokine release (such as transient fever or hypotension) must be monitored more vigilantly.
Binetrakin must be administered by a healthcare professional in a clinical setting equipped to handle potential infusion or injection reactions.
Because Binetrakin is typically administered in a hospital or clinic, missed doses are rare. If a scheduled dose is missed, contact your healthcare provider immediately to reschedule. Do not attempt to 'double up' on doses to make up for a missed one, as this significantly increases the risk of severe side effects.
An overdose of Binetrakin can lead to a condition known as 'Cytokine Storm' or severe Cytokine Release Syndrome (CRS). Symptoms include high fever, severe hypotension (low blood pressure), pulmonary edema (fluid in the lungs), and multi-organ failure.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency of administration without explicit medical guidance.
Most patients receiving Binetrakin will experience some degree of 'flu-like' symptoms, which are a direct result of the drug's mechanism of activating the immune system. These typically appear 4 to 12 hours after administration:
> Warning: Stop taking Binetrakin and call your doctor or emergency services immediately if you experience any of the following:
Because Binetrakin is often used for short-term hematopoietic recovery or in specific cycles, long-term data is still being gathered. Potential long-term concerns include:
Currently, Binetrakin does not carry a specific FDA Black Box Warning; however, similar interleukin-based therapies (like Aldesleukin/IL-2) carry warnings for Capillary Leak Syndrome and Severe Infection Risk. Patients should be aware that Binetrakin is a potent immunomodulator that can cause systemic inflammatory responses.
Report any unusual symptoms, no matter how minor they seem, to your healthcare provider immediately. Early intervention is key to managing cytokine-related side effects.
Binetrakin is a high-potency biological agent. It should only be administered by clinicians experienced in the use of cytokines and biological response modifiers. Patients must be closely monitored for at least several hours following each dose to ensure that any immediate adverse reactions are treated promptly. It is vital to disclose your full medical history, especially any history of autoimmune disease or chronic infections, before starting treatment.
No FDA black box warnings are currently issued for Binetrakin as of early 2026. However, its use is restricted to specialized indications, and the potential for severe systemic inflammation (Cytokine Release Syndrome) is a primary safety concern that clinicians treat with the same gravity as a boxed warning.
Patients undergoing treatment with Binetrakin require frequent laboratory testing to ensure safety and efficacy:
Binetrakin frequently causes significant fatigue, dizziness, and 'brain fog' (cognitive impairment) during the 24-48 hours following a dose. Patients should not drive, operate heavy machinery, or engage in hazardous activities until they are certain the medication does not impair their mental or physical abilities.
Alcohol should be avoided during treatment with Binetrakin. Alcohol can exacerbate the dehydration associated with fever and may increase the risk of liver toxicity when combined with the drug's potential effects on hepatic enzymes.
Binetrakin does not typically require a tapering schedule because it is not a steroid or a habit-forming substance. However, stopping the drug before a full course is completed (in an oncology setting) may result in suboptimal therapeutic outcomes. If the drug is stopped due to toxicity, the side effects usually resolve within 72 hours as the protein is cleared from the system.
> Important: Discuss all your medical conditions, including any history of depression or mental health issues, with your healthcare provider before starting Binetrakin, as cytokines can sometimes affect mood.
Binetrakin can significantly alter the results of various laboratory tests:
For each major interaction, the management strategy involves either avoiding the combination entirely or performing daily clinical and laboratory assessments to detect early signs of toxicity or reduced efficacy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
Binetrakin must NEVER be used in the following circumstances:
In these cases, a healthcare provider will perform a careful risk-benefit analysis:
There is a potential for cross-sensitivity with other recombinant cytokine products. Patients who have had adverse reactions to Interferon-alpha or Interleukin-2 may be at a higher risk for reacting to Binetrakin, although the mechanisms are not identical. Always inform your allergist or immunologist if you are starting Binetrakin therapy.
> Important: Your healthcare provider will evaluate your complete medical history, including any 'hidden' conditions like dormant tuberculosis or hepatitis B, before prescribing Binetrakin.
Binetrakin is classified under FDA Pregnancy Category C (or the equivalent modern labeling). There are no adequate and well-controlled studies of Binetrakin in pregnant women. Animal reproduction studies have shown that high doses of IL-12 can increase the risk of fetal loss (miscarriage) and may interfere with normal placental development.
It is not known whether Binetrakin is excreted in human milk. Because many drugs and large proteins are excreted in milk, and because of the potential for serious adverse reactions in nursing infants (such as immune system modulation), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of Binetrakin in pediatric patients have not been established through standard clinical trials. However, under the FDA 'Animal Rule,' Binetrakin may be authorized for use in children for the treatment of acute radiation syndrome. In these cases, dosing is carefully adjusted for weight. Parents should be aware that children may experience more intense febrile (fever) reactions than adults.
Clinical studies of Binetrakin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
In patients with renal impairment, the primary concern is not the clearance of the drug itself, but the management of side effects like hypotension and fluid shifts. Patients with a GFR (Glomerular Filtration Rate) below 30 mL/min require careful monitoring of fluid balance and electrolytes during Binetrakin therapy. It is not significantly cleared by hemodialysis.
Binetrakin should be used with caution in patients with Child-Pugh Class B or C hepatic impairment. While the liver does not metabolize the drug via the CYP450 system, the systemic inflammatory response can exacerbate pre-existing liver inflammation. Baseline and twice-weekly liver function tests are recommended in this population.
> Important: Special populations require individualized medical assessment and often require a multidisciplinary team of specialists to manage therapy safely.
Binetrakin is a recombinant human interleukin-12 (rhIL-12). It acts as a potent agonist at the IL-12 receptor. Upon binding, it triggers the JAK-STAT signaling pathway, specifically activating STAT4. This leads to the transcriptional activation of genes responsible for the production of Interferon-gamma (IFN-γ) and the maturation of Th1 cells. Furthermore, it enhances the lytic activity of NK cells and CD8+ T-cells by upregulating the expression of perforins and granzymes, the 'tools' these cells use to destroy target cells.
The pharmacodynamic effect of Binetrakin is most easily measured by the rise in serum IFN-γ levels, which typically peaks 24 hours after administration. There is a clear dose-response relationship between the amount of Binetrakin administered and the magnitude of the cytokine response. Duration of effect: A single dose can maintain elevated levels of activated T-cells for up to 7 days. Tolerance: Unlike some drugs, 'tachyphylaxis' (rapidly diminishing response) is not commonly seen with Binetrakin, though the body's feedback loops may eventually dampen the response over several weeks of continuous use.
| Parameter | Value |
|---|---|
| Bioavailability | ~60-80% (Subcutaneous) |
| Protein Binding | Minimal (primarily receptor-bound) |
| Half-life | 12 - 24 hours |
| Tmax | 8 - 12 hours |
| Metabolism | Proteolytic degradation |
| Excretion | Minimal Renal; primarily cellular catabolism |
Binetrakin is classified as a Lymphocyte Growth Factor [EPC] and a cytokine. It is related to other interleukins like Aldesleukin (IL-2) and Oprelvekin (IL-11), but it is unique in its specific focus on the Th1/IFN-γ axis. It is also categorized as a Non-Standardized Plant/Food Allergenic Extract [EPC] in some regulatory contexts due to the methods used in certain manufacturing processes or historical classification groupings.
Medications containing this ingredient
Common questions about Binetrakin
Binetrakin is primarily used as a lymphocyte growth factor to stimulate the immune system and help the body recover after severe bone marrow damage. It is most notably indicated for the treatment of the hematopoietic syndrome associated with Acute Radiation Syndrome (ARS). By promoting the production of white blood cells and natural killer cells, it helps the body fight off infections that occur when the immune system is compromised. Additionally, it has been investigated in clinical trials as an immunotherapy for certain types of cancer, such as melanoma and lymphoma. Your healthcare provider will determine if its use is appropriate based on your specific medical needs.
The most common side effects of Binetrakin are 'flu-like' symptoms that occur as the immune system is activated. These include fever, chills, fatigue, headache, and muscle aches, which typically appear within hours of the injection. Many patients also experience redness, pain, or swelling at the injection site. Nausea and a general feeling of being unwell (malaise) are also frequently reported. These symptoms are usually temporary and can often be managed with over-the-counter medications like acetaminophen, as directed by a doctor. Always report any side effects to your medical team to ensure they are managed correctly.
It is generally advised to avoid alcohol while receiving Binetrakin treatment. Alcohol can dehydrate the body, which may worsen the fever and headaches commonly caused by the medication. Furthermore, both Binetrakin and alcohol can put stress on the liver; combining them may increase the risk of liver enzyme elevations or liver damage. Alcohol can also interfere with your ability to monitor yourself for serious side effects like dizziness or confusion. To ensure the safest and most effective treatment, it is best to refrain from alcohol use. Discuss any concerns about alcohol with your healthcare provider.
The safety of Binetrakin during pregnancy has not been fully established in human studies. Animal data suggests that high doses of interleukin-12 may increase the risk of pregnancy loss or developmental issues. Because of these potential risks, Binetrakin is typically only used during pregnancy if the mother's life is at risk, such as in an emergency radiation exposure scenario. Women who are pregnant or planning to become pregnant should have a detailed discussion with their doctor about the risks and benefits. Effective contraception is often recommended for women of childbearing age during treatment. Your doctor will provide guidance based on the latest clinical evidence.
The onset of Binetrakin's biological activity is relatively rapid, with immune system signaling beginning within hours of the injection. However, the visible clinical effects, such as an increase in white blood cell counts, usually take several days to become apparent. Peak levels of interferon-gamma, a key marker of the drug's activity, are typically seen about 24 hours after a dose. For patients recovering from radiation or chemotherapy, it may take one to two weeks to see a significant improvement in blood cell levels. The total duration of treatment depends on how quickly the bone marrow recovers. Frequent blood tests will be used to monitor your progress.
Binetrakin is typically administered in a controlled medical setting for a specific number of doses, so the concept of 'stopping suddenly' is different than with daily oral medications. If you are receiving a series of injections for cancer or bone marrow support, missing a dose can reduce the effectiveness of the treatment. However, Binetrakin does not cause physical dependence, so stopping it will not cause withdrawal symptoms like those seen with steroids or opioids. If the medication is stopped due to a severe side effect, the 'flu-like' symptoms usually fade within a few days. Always consult your oncologist or hematologist before making any changes to your treatment schedule.
If you miss an appointment for a Binetrakin injection, you should contact your healthcare provider or clinic as soon as possible to reschedule. Timing can be very important, especially when Binetrakin is used to help the immune system recover after radiation or chemotherapy. Do not attempt to self-administer the medication or take an extra dose to make up for the one you missed. Your medical team will determine the best way to get your treatment back on track. Keeping a calendar of your appointments can help ensure you receive the medication at the optimal intervals. If you have questions about the dosing schedule, your pharmacist or nurse can provide clarification.
Weight gain is not a typical side effect of Binetrakin; in fact, weight loss is more common. Many patients experience a loss of appetite (anorexia) or nausea during treatment, which can lead to temporary weight loss. However, some patients may experience 'fluid retention' or swelling (edema) as part of an inflammatory response, which might cause a temporary increase in the number on the scale. This is not the same as gaining body fat and should be reported to a doctor, as it could indicate a more serious reaction. If you notice sudden or significant weight changes, your healthcare provider will evaluate the cause. Maintaining adequate nutrition and hydration during therapy is very important.
Binetrakin can interact with several other types of medications, particularly those that affect the immune system. For example, taking corticosteroids or other immunosuppressants can block the beneficial effects of Binetrakin. It may also interact with other cytokine therapies, potentially increasing the risk of a dangerous systemic inflammatory response. Because it can lower blood pressure, it may also interact with antihypertensive drugs. It is essential to provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. Your doctor will carefully coordinate your medications to avoid harmful interactions.
No, Binetrakin is a complex biological product (a recombinant protein) and is not currently available as a generic medication. In the world of biologics, similar products are called 'biosimilars' rather than generics. As of 2026, there are no FDA-approved biosimilars for Binetrakin. Because it is a specialized medication used in specific clinical settings, it is usually only available through hospital pharmacies or specialized treatment centers. The cost and availability are typically managed through your health insurance and the treating facility. If you have concerns about the cost of the medication, your hospital's financial counselor may be able to assist you.